Connect Biopharma Holdings Ltd（CNTB）股票分析

AI 分析 of Connect Biopharma Holdings Ltd (CNTB)

卖出

Connect Biopharma Holdings Ltd is not a good buy right now due to its current price of $0.7771, which is significantly below its 52-week high of $3.82, indicating a steep decline of approximately 80%. The RSI of 28.565 suggests the stock is oversold, but the overall financial performance shows a troubling trend with a net income loss of $17,284,000 in the latest quarter. Furthermore, the forward P/E ratio of 0.7669 indicates potential undervaluation, but the company has not yet proven consistent revenue generation, with a year-to-date change of -69.16%. The main risk is the substantial net margin loss of -624.42% in the latest quarter, which raises concerns about the company's sustainability and ability to recover.

估值指标

Connect Biopharma Holdings Ltd（CNTB）当前预期市盈率为 0.77，5 年平均预期市盈率为 -2.02。

预期市盈率

高估

5 年均值 P/E

-2.02

当前P/E

0.77

高估

0.52

低估

-4.56

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

0.02

当前EV/EBITDA

-0.04

高估

0.66

低估

-0.62

预期市销率

合理

5 年均值 P/S

1966.31

当前P/S

0.49

高估

10717.76

低估

-6785.13

Alphio AI 对 CNTB 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%CNTB

$1.88

情景价格

基

基准

基准 · 50%CNTB

$1.56

情景价格

悲

悲观

悲观 · 25%CNTB

$1.53

情景价格

持有 CNTB 的大户

Q

Qiming Weichuang Venture Capital Management (Shanghai) Company Limited

+ 持有CNTB

+0.00%

3个月收益率

CNTB 常见问题 —— 由 Alphio AI 解答

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Connect Biopharma Holdings Ltd is not a good buy right now due to its current price of $0.7771, which is significantly below its 52-week high of $3.82, indicating a steep decline of approximately 80%. The RSI of 28.565 suggests the stock is oversold, but the overall financial performance shows a troubling trend with a net income loss of $17,284,000 in the latest quarter. Furthermore, the forward P/E ratio of 0.7669 indicates potential undervaluation, but the company has not yet proven consistent revenue generation, with a year-to-date change of -69.16%. The main risk is the substantial net margin loss of -624.42% in the latest quarter, which raises concerns about the company's sustainability and ability to recover.